"A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)"

drug protocol number
D3614C00001
drug sponsor
AstraZeneca
drug study
Capivasertib
drug trial site
KFSH-D
drug status
Ongoing
drug phase